Trials / Completed
CompletedNCT02537444
Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191)
A Phase 2 Proof-of-Concept Study of ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Recurrent Ovarian Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 78 (actual)
- Sponsor
- Acerta Pharma BV · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To characterize the safety and efficacy of acalabrutinib (ACP-196) monotherapy and acalabrutinib plus pembrolizumab combination therapy in subjects with recurrent ovarian cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Acalabrutinib | |
| DRUG | acalabrutinib and pembrolizumab combination |
Timeline
- Start date
- 2015-11-01
- Primary completion
- 2018-07-01
- Completion
- 2018-10-01
- First posted
- 2015-09-01
- Last updated
- 2019-09-25
- Results posted
- 2019-09-12
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02537444. Inclusion in this directory is not an endorsement.